efficacy of tirzepatide for the treatment adults with type 2 diabetes: An endocrine perspective Tirzepatide for the Maintenance of

Apart from the well-characterised gastrointestinal (GI) adverse events (AEs), GLP-1R agonists are generally well tolerated [2,3,4]

Dexras1, a small gtpase, is required for glutamate-nmda neurotoxicity

In a Phase 1 trial, three once-monthly injections of 420 mg of maridebart cafraglutide in overweight/obese individuals without diabetes reduced body weight by 14%, and most of the weight loss was maintained for 23 months after treatment was discontinued [54]

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2

1000mg daily dosage for skin clarity, repair, and cellular protection